Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Oculus Innovative SC (OCLS)

Oculus Innovative SC (OCLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Oculus Innovative SC 1129 N. MCDOWELL BLVD. PETALUMA CA 94954

www.oculusis.com P: 707-283-0550

Description:

OCULUS INNOVATIVE SCIENCES, INC. is a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to help prevent and treat infections in chronic and acute wounds. The Microcyn Technology platform is a biocompatible, shelf-stable solution containing active oxychlorine compounds that is currently commercialized outside the United States (Europe, India and Mexico) for the treatment of infected wounds. The solutions derived from the Microcyn Technology platform have demonstrated, in a variety of research and investigational studies, the ability to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria (including MRSA and VRE), viruses, fungi and spores. A recently completed U.S. Phase II clinical trial of Microcyn Technology met the primary endpoints of safety and efficacy for the treatment of mildly infected diabetic foot ulcers.

Key Statistics

Overview:

Market Capitalization, $K 20,510
Shares Outstanding, K 4,200
Annual Sales, $ 15,080 K
Annual Net Income, $ -10,160 K
Last Quarter Sales, $ 4,110 K
Last Quarter Net Income, $ -1,950 K
60-Month Beta 1.63
% of Insider Shareholders 7.70%
% of Institutional Shareholders 6.73%

Growth:

1-Year Return -14.66%
3-Year Return -74.62%
5-Year Return -89.75%
5-Year Revenue Growth 54.67%
5-Year Earnings Growth -71.89%
5-Year Dividend Growth 0.00%

Per-Share Information:

Latest Earnings Date 11/10/16
Earnings Per Share ttm -2.82
EPS Growth vs. Prev Qtr 24.59%
EPS Growth vs. Prev Year 16.36%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-5 on 06/27/16

OCLS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -126.66%
Return-on-Assets % -90.07%
Profit Margin % -67.37%
Debt/Equity 0.82
Price/Sales 1.36
Price/Cash Flow N/A
Price/Book 3.45
Book Value/Share 1.44
Interest Coverage 0.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar